AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,104.00p
   
  • Change Today:
    -220.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,667.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.68m
  • Volume: 2,174,580
  • Market Cap: £172,188m
  • RiskGrade: 123
  • Beta: 0.01

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.
Registrars: Equiniti
Brands: Losec, Prilosec, Nexium, Crestor

Key Personnel

Senior Independent Non-Executive Director: Philip A J Broadley
CEO and Executive director: Pascal Soriot
CFO & Executive Director: Aradhana Sarin
Chairman: Michel Demare
Independent Non-Executive Director: Euan Ashley
Independent Non-Executive Director: Sheri McCoy
Independent Non-Executive Director: Diana Layfield
Independent Non-Executive Director: Tony Mok
Independent Non-Executive Director: Nazneen Rahman
Non-Executive Dir: Karen Knudsen, Anna Manz, Rene Haas, Birgit Conix , Marcus Wallenberg

Contact Details

Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge,United Kingdom, CB2 0AA
Phone: +44 (0)20 3749 5000
Fax: +44 (0)20 7604 8151
Website: http://www.astrazeneca.com

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE 100, FTSE 350, FTSE All-Share
Overseas Listings: BATSLON:AZNL
ISIN: GB0009895292

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,104.00p
Change Today -220.00p
% Change -1.94 %
52 Week High 13,276.00
52 Week Low 9,667.00
Volume 2,174,580
Shares Issued 1,550.68m
Market Cap £172,188m
Beta 0.01
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.11% below the market average94.11% below the market average94.11% below the market average94.11% below the market average94.11% below the market average
86.05% below the sector average86.05% below the sector average86.05% below the sector average86.05% below the sector average86.05% below the sector average
Price Trend
45.18% below the market average45.18% below the market average45.18% below the market average45.18% below the market average45.18% below the market average
91.11% above the sector average91.11% above the sector average91.11% above the sector average91.11% above the sector average91.11% above the sector average
Income
64.72% below the market average64.72% below the market average64.72% below the market average64.72% below the market average64.72% below the market average
Sector averageSector averageSector averageSector averageSector average
Growth
87.40% above the market average87.40% above the market average87.40% above the market average87.40% above the market average87.40% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 14
Neutral 5
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 07-Aug-25 20-Feb-25
Paid 08-Sep-25 24-Mar-25
Amount 103.00¢ 210.00¢

Trades for 01-Aug-2025

Time Volume / Share Price
14:51 0 @ 11,146.00p
14:51 0 @ 11,146.00p
14:51 2 @ 11,146.00p
14:51 2 @ 11,152.00p
16:45 239,361 @ 11,043.10p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page